Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150797 · ClinicalTrials.gov registry record · Phase 2
Melatonin for Adolescent Migraine Prevention Study
A Phase 2 study, sponsored by Amy Gelfand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT03150797: Clinical Trial Phase 2 study, sponsored by Amy Gelfand.
NCT03150797 is a Phase 2 study that was terminated before completion, run by Amy Gelfand. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03150797, a Phase 2 study, was terminated before completion, sponsored by Amy Gelfand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each participant will be 4 months.
Primary Outcome
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate).
Interventions
- DRUG Melatonin
- DRUG Placebo oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
Why NCT03150797 stopped before completion
NCT03150797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Melatonin is the first listed.
NCT03150797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03150797 about?
NCT03150797 is a clinical study titled "Melatonin for Adolescent Migraine Prevention Study". This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each...
What is the current status of trial NCT03150797?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2017-08-02. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT03150797?
The interventions under investigation include: Melatonin (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03150797?
This trial is sponsored by Amy Gelfand, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03150797's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI